Regulatory approval
Published by the Health Service Executive. Approved
In combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor 2 (HER2)-negative early breast cancer at high risk of recurrence.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| HSE (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| HSE (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| HSE (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib | |
| HSE (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib | |
| HSE (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-10-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |